sample
INDICATION
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.

Provider

Information and Educational Resources

Provides guidance for submitting a prior authorization for XIFAXAN when needed
Whether your patient is newly diagnosed or is just newly on XIFAXAN, give him/her the support needed to help reduce the risk of OHE recurrence.
Your eligible patients may be entitled to medications for no more than $8.95/prescription, which is a Medicare Part D benefit.
Offers information providers should share when a patient is discharged to them from the hospital
Offers information providers should share when a patient is discharged to them from the hospital

Fillable Forms

A standard form for a patient-specific letter of medical necessity to explain your clinical decision making in choosing a therapy
Use to reduce the cost share of a medication. Follows submission of a PA or Utilization Management request.
Use your free login to submit ePA form.

Identify a caregiver whenever possible who will help the patient with his or her treatment plan.

Caregiver and Patient

Information and Educational Resources

Provides most eligible, commercially insured patients help with their monthly co-pays for XIFAXAN
Provides information about XIFAXAN insurance coverage and prescription savings
Instructions for setting up alerts on an iPhone, Android, or Apple Watch

Video

This video will help patients with OHE understand their medication and the importance of ongoing disease management to help reduce the risk of OHE recurrence.

Caregiver and Patient 02

Resources 02

Provides most eligible, commercially insured patients help with their monthly co-pays for XIFAXAN. PLEASE NOTE: This tool can not be printed.
Provides information about XIFAXAN coverage, prescription savings and how to sign up for the HE Living Program (H.E.L.P.).
Instructions for setting up alerts on an iPhone, android or Apple Watch.
Back to Top
Email
View/Print
Copy Link
IMPORTANT SAFETY INFORMATION

XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.

Please click here for full Important Safety Information.
Copy to Clipboard
Checkbox is not selected